At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 3 enrolled
Drug / intervention
Ixazomibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma
In Brief
A Early Phase 1 clinical trial evaluating Ixazomib for Glioblastoma. Completed, enrolled 3 participants across 1 site.
Detailed Summary
This phase 0 trial studies ixazomib citrate in treating patients with glioblastoma that has spread or returned after period of improvement who are planning to undergo surgery. When given by mouth, ixazomib may be able to reach tumor cells in the brain. Studying samples of tissue, blood, and plasma in the laboratory from patients receiving ixazomib may help doctors learn more about the effects of ixazomib on the cells. It may also help doctors understand how well patients will respond to treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma
CountriesUnited States
CollaboratorsTakeda
Timeline
Early Ph 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 2015
Enrollment StartMar 2016
Primary CompletionJul 2018
Study CompletionSep 2020
TodayJul 2026
First PostedDec 15, 2015
Enrollment StartMar 24, 2016
Primary CompletionJul 1, 2018
Study CompletionSep 3, 2020
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 10.5 years ago
Interventions
Ixazomibdrug
Given PO